

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

BAZAN et al.For: MAMMALIAN CYTOKINES; RELATED
REAGENTS AND METHODS

Application No.: 10/601,105

Filed: 06/20/2003

Examiner: Skelding, Zachary S.

Group Art Unit: 1644

Date: August 8, 2007

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENTCommissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
Mail Stop: **AMENDMENT**

Sir:

Pursuant to the duty of disclosure under 37 C.F.R §1.56, it is requested that the documents listed on the accompanying Forms PTO/SB.08a and 08b be considered and made record in the above-identified patent application. Other than cited U.S. patents and published patent applications, copy(ies) of these documents ☐ are enclosed ☒ were filed in related U.S. Application No(s) 09/963,347 filed 09/25/2001. Since the Examiner is believed to have ready access to the cited U.S. patents and published patent applications, copies of these documents are not herewith transmitted, but will be provided upon request.

(b) No fee is believed due because:

- ☐ This Information Disclosure Statement is being submitted concurrently with the filing of the above-identified application; **or**
- ☐ This Information Disclosure Statement is being submitted within three (3) months of the filing date of the above-identified application, **or**
- ☐ This Information Disclosure Statement is being submitted concurrently with a Request for Continued Examination (RCE), **or**
- ☐ This Information Disclosure Statement is being submitted prior to the mailing of a first Office Action on the merits.

(c) ☒ This Information Disclosure Statement is being submitted before the mailing date of any final action, notice of allowance or an action that otherwise closes prosecution; and

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; **or**

☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement; **or**

☒ The Commissioner is hereby authorized to charge the requisite fee.

(d) ☐ This Information Disclosure Statement is being submitted on or before the payment of the issue fee; and

☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; **or**

☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement; **and**


☐ The Commissioner is hereby authorized to charge the requisite fee.

☒ The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 19-0365.

Respectfully submitted,
SCHERING-PLOUGH CORPORATION

Dated: August 8, 2007
SCHERING-PLOUGH CORPORATION
Patent Department, K-6-1, 1990
2000 Galloping Hill Road
Kenilworth, NJ 07033-0530
Facsimile No.: (908) 298-5388

By:


Name: Gloria M. Fuentes
Reg. No.: 47,580
Attorney of Record
Telephone No.: (908) 298-2266

SUBSTITUTE FOR FORM 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE AS MANY SHEETS AS NECESSARY)		ATTYY. DOCKET NO.: DX0903K1B SERIAL NO.: 10/601,105 APPLICANT: Fernando Bazan et al. EXAMINER NAME: Skelding, Zachary S. FILING DATE: 06/20/2003 ART UNIT: 1644	
Sheet 1 of 1			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
Examiner initials*	Cite no. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AA	VALENZONA <i>et al.</i> , "Exogenous Interleukin 7 as a Proliferative Stimulant of Early Precursor B Cells in Mouse Bone Marrow: Efficacy of IL-7 Injection, IL-7 Infusion and IL-7-Anti-IL-7 Antibody Complexes," Cytokine, Vol. 10, No. 6, pgs. 404-412 (June 1998)	
	AB	MIYAJI, <i>et al.</i> , "A Comparison of Proliferative Response to IL-7 and Expression of IL-7 Receptors in Intermediate TCR Cells of the Liver, Spleen, and Thymus," Cellular Immunology Vol. 169, Article 0106, pgs. 159-165 (1996)	
	AC	PEARSON, <i>et al.</i> , "Effective Protein Sequence Comparison," Methods in Enzymology, Vol. 266, pgs. 227-258 (1996)	
	AD	MOTT, <i>et al.</i> , "Four-Helix Bundle Growth Factors and Their Receptors: Protein-Protein Interactions," Current Opinion in Structural Biology, Vol. 5, No. 1, pgs. 114-121 (1995)	
	AE	WINKLER, <i>et al.</i> , "Interleukin-3 and Interleukin-7 Are Alternative Growth Factors for the Same B-Cell Precursors in the Mouse," Blood, Vol. 85, pgs. 2045-2051 (1995)	
	AF	AL-SHAMI, <i>et al.</i> , "A Role for Thymic Stromal Lymphopoietin in CD4+ T Cell Development," The Journal of Experimental Medicine, Vol. 200, No. 2, pgs. 159-168 (2004)	
	AG	COSENZA, <i>et al.</i> , "Disulfide Bond Assignment in Human Interleukin-7 by Matrix-Assisted Laser Desorption/Ionization Mass Spectroscopy and Site-Directed Cysteine to Serine Mutational Analysis," The Journal of Biological Chemistry, Vol. 272, No. 52, pgs. 32995-33000 (1997)	
	AH	KRUSE, <i>et al.</i> , "Two Distinct Functional Sites of Human Interleukin 4 Are Identified by Variants Impaired in Either Receptor Binding or Receptor Activation," The EMBO Journal, Vol. 12, No. 13, pgs. 5121-5129 (1993)	
	AI	KROEMER, <i>et al.</i> , "Prediction of the Three-Dimensional Structure of Human Interleukin-7 by Homology Modeling," Protein Engineering, Vol. 9, No. 6, pgs. 493-498 (1996)	
	AJ	OSBORN, <i>et al.</i> , "Overexpression of Murine TSLP Impairs Lymphopoiesis and Myelopoiesis," Blood, Vol. 103, No. 3, pgs. 843-851 (2004)	
	AK	QUENTMEIER, <i>et al.</i> , "Cloning of Human Thymic Stromal Lymphopoietin (TSLP) and Signaling Mechanisms Leading to Proliferation," Leukemia, Vol. 15, No. 8, pgs. 1286-1292 (2001)	
Examiner signature:		Date considered:	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.